{
    "clinical_study": {
        "@rank": "89196", 
        "acronym": "CHOICE", 
        "biospec_descr": {
            "textblock": "blood,tumor and adjacent normal tissue samples"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "This is an epidemiological,multicenter study of genomic and expression profiles of patients\n      with newly diagnosed NSCLC.Two hundred and fifty NSCLC patients who fulfill the criteria are\n      to be recruited by investigational sites.Approximately 100 of them will be from\n      retrospectively collected samples with detailed clinical and 2-year follow-up information\n      after surgeries.The demographics,cancer/adjacent normal tissue and matched blood sample will\n      be collected after the patient had provided informed consent.All tissue samples will be\n      analyzed for somatic mutations by exome deep sequencing,mRNA expression profiling by RNA\n      sequencing and chromosome copy number variation by SNP array at the designated laboratories."
        }, 
        "brief_title": "Study of Blood, Tumor and Adjacent Normal Tissue Samples From Chinese Smoking Induced Lung Cancer Patients", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Non Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "The 2-year follow-up information of all enrolled patients will be collected every 6 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Provision of written informed consent.\n\n          2. Male or female aged\u226518 years.\n\n          3. .Histological or cytologically confirmed primary NSCLC\uff0cincluding histological\n             subtypes:adenocarcinoma,squamous cell carcinoma and large cell carcinoma etc.\n\n          4. .Provision of surgical specimen and blood sample.The retrospective samples will be\n             collected between 2006and 2012 from the bio-bank.\n\n          5. Patients must be willing to provide detailed clinical information (sex,age,geographic\n             place,tumor stage,grade,size,smoking history,treatment history if any and outcome\n             data).\n\n          6. Heavy smokers(defined as having smoked 20 pack-years or more).\n\n          7. Treatment naive patients:No prior chemotherapy,biological,immunological therapy or\n             radical radiotherapy is permitted.\n\n        Exclusion Criteria:\n\n          -  Not applicable"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "The study aims to collect approximately 250 smoking induced lung cancer(NSCLC)\n        samples.Approximately 200 cases of treatment naive samples will be required. Samples will\n        be collected mainly from the investigational sites in Guangzhou, Shanghai and Beijing that\n        have expertise in lung cancer diagnosis."
            }
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02113852", 
            "org_study_id": "CTONG 1308"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Non small cell Lung Cancer", 
            "Heavy smokers", 
            "Treatment naive patients"
        ], 
        "lastchanged_date": "April 14, 2014", 
        "number_of_groups": "1", 
        "official_title": "Study of Blood, Tumor and Adjacent Normal Tissue Samples From Chinese Smoking Induced Lung Cancer Patients", 
        "overall_official": {
            "affiliation": "Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences", 
            "last_name": "Yi-Long Wu, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To indentify and characterize somatic mutations in coding region(exome) in NSCLC patients through next generation sequencing of the tumor and blood samples.To identify and characterize whole genome copy number variation in NSCLC patients by using the standard SNP array(Affymetrix SNP6.0).To indentify and characterize the transcriptiome of tumor versus adjacent normal tissues by using RNA sequencing.", 
            "measure": "whole genome copy number variation in NSCLC patients", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02113852"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To identify the changes in molecular pathways and biomarker related to smoking induced lung cancer to help establish more effective therapy for lung cancer treatment in the future.", 
            "measure": "Establish more effective therapy for lung cancer treatment in the future", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "source": "Guangdong Association of Clinical Trials", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Guangdong Association of Clinical Trials", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "N/A", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "2 Years", 
        "verification_date": "April 2014"
    }
}